Thank you to Ocular Therapeutix for being a Silver Sponsor of the EBAA 2021 Annual Meeting.
Sponsored Session: Research and Surgical Innovation: The Lasting Impact of Ocular Donation (Thursday, June 10 at 11 AM EDT)
Ocular Therapeutix is a biopharmaceutical company aspiring to be a leader in ophthalmology by leveraging its proprietary hydrogel technology to develop transformational drug products that enhance the patient and provider experience. DEXTENZA, the first and only ophthalmic steroid insert is FDA approved for the treatment of ocular inflammation and pain following ophthalmic surgery.
DEXTENZA provides patients with an alternative to eye drops. One insert provides the delivery of preservative-free steroid directly to the ocular surface for up to 30 days. No pharmacy visit, no touching the face and no burden of steroid drop administration required with DEXTENZA.
Warnings/Precautions: Increased IOP, bacterial/viral/fungal infections and delayed healing.